Moderna begins Phase 1/2 trial for experimental flu vaccine
Shares of Moderna Inc.
MRNA,
-0.41%
were down 0.6% in premarket trading on Wednesday after the company said it began dosing patients in a Phase 1/2 clinical trial evaluating an experimental seasonal flu vaccine. The study is expected to enroll 180 adults…
